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332 The Journal of Thoracic and Cardbjective: We sought to investigate immune cell kinetics in relation to skeletal
yoblast survival and heart function improvement after nonautologous skeletal
yoblast transplantation in a rat model of myocardial infarction.
ethods: One week after myocardial infarction, 208 Wistar rats were grouped into
roup 1 (n 24, receiving 150 L of medium only), group 2 (n 24, receiving 150
L of medium and cyclosporine [INN: ciclosporin]), group 3 (n  40, human
keletal myoblast transplantation), group 4 (n  40, human skeletal myoblast
ransplantation with cyclosporine treatment), group 5 (n  40, rat skeletal myoblast
ransplantation), and group 6 (n  40, rat skeletal myoblast transplantation with
yclosporine treatment). The hearts were harvested at 10 minutes and 1, 4, 7, and 28
ays after cell transplantation. Skeletal myoblast survival was confirmed by means
f immunohistochemical studies and quantified by using real-time polymerase chain
eaction. Host immune responses were assessed by immunostaining for macro-
hages and CD4 and CD8 lymphocytes. Heart function was evaluated by means
f echocardiographic analysis.
esults: The majority of macrophages and lymphocytes infiltrated in the acute phase
from day 1 to day 7) and then subsided by day 28. The donor skeletal myoblasts
urvived and differentiated well in all skeletal myoblast transplantation groups.
llogeneic skeletal myoblasts showed a superior survival rate than xenogeneic skeletal
yoblasts (P  .01). Cyclosporine inhibited the infiltration of the immunocytes,
nhanced skeletal myoblast survival, and improved heart performance compared with
hat seen in the groups not receiving cyclosporine treatment (P  .05).
onclusions: Allomyoblasts survive better than do xenomyoblasts after transplan-
ation into infarcted myocardium. After inhibition of immunocyte infiltration by
eans of immunosuppressive treatment, skeletal myoblast survival is enhanced,
ith improved heart performance. These findings suggest the feasibility of nonau-
ologous myoblast transplantation with immunosuppressive treatment.
ell-based cardiac repair represents a promising therapeutic approach for
heart failure. Among various cell types, skeletal myoblasts (SkMs) have
been extensively used for cardiac cell therapy because of their myogenic
otential, proliferative capacity, resistance to ischemia, and nontumorigenic nature.
reclinical studies in both small- and large-animal models showed a definite
mprovement in regional and global left ventricular heart function after SkM
ngraftment.1-6 Most of these studies involved SkMs from either autologou
yngeneic donors.1-4 We have previously reported long-term survival of xenom
lasts using transient immunosuppressive treatment.5,6 On the other hand, mo
linical studies used autologous SkMs for cardiac repair because their use precluded
he concern of immune rejection.7-10 However, the use of autologous SkMs is t
onsuming and less cost-effective and has logistic concerns for large-scale clinical
iovascular Surgery ● November 2007
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TXpplications. The use of SkMs from nonautologous sources
ight overcome these problems and provide alternate
hoices for clinicians. The present study provides direct
omparison between allomyoblasts and xenomyoblasts after
ngraftment with respect to their survival, immunologic
ehavior, and graft efficacy for cardiac repair. In this study
e transplanted equal numbers of SkMs purified from male
ats and human donors into a female rat model of myocar-
ial infarction to compare their in vivo behavior. This was
one to provide us with a better understanding of the early
ellular behavior of allomyoblasts and xenomyoblasts and
he underlying mechanisms that govern early graft attrition
fter engraftment into the infarcted heart.
aterials and Methods
he work was approved by the Institutional Review Board and
nstitutional Animal Care and Use Committee protocols of the
ational University of Singapore.
solation and Expansion of SkMs
uman SkMs (hSkMs; kindly provided by Cell Transplants Sin-
apore, Ltd) were isolated from a 20-year-old pathogen-free male
onor who provided written consent and were expanded until the
equired number was achieved. Rat SkMs (rSkMs) were isolated
rom male Wistar rats. Isolation of cells was performed as de-
cribed previously.11 Forty-eight hours before muscle harvest, 
L of bupivacaine (0.5%, Astra) was injected into the tibialis anterior
uscles of rat hind limbs to achieve a better cell yield. Skeletal
uscle (1 g) was harvested, minced, and enzymatically dissociated
ith collagenase IA (2 mg/mL, Sigma) for 1 hour, dispase (2.4 U/mL,
nvitrogen) for 1 hour, and trypsin–ethylenediamine tetraacetic acid
0.25%, Sigma) for 30 minutes. The muscle cell extract was preplated
times at regular time intervals to increase the purity of the purified
kMs. The cells were cultured in patented Super Medium (Cell
ransplants Singapore, Ltd) for 4 days after initial seeding and
hen fed with Dulbecco’s modified Eagle’s medium (DMEM)
upplemented with 20% fetal bovine serum, 100 U/mL penicillin,
00 g/mL streptomycin, and 0.1 mg/mL L-glutamine until the
equired number was achieved. The purity of SkMs was assessed
y means of immunostaining and flow cytometric analysis for
esmin expression with desmin-specific antibody (1:50, Sigma).
reparation of SkMs Before Transplantation
or posttransplantation identification, SkMs were double-labeled
ith the lac-z reporter gene and 4=,6=-diamidino-2-phenylindole
ydrochloride (DAPI; Sigma).
SkMs were grown to achieve 60% confluence. The cells were
rst incubated in 15 mL of transduction medium containing 1 
06 particles/mL retroviral vector carrying the lac-z reporter gene.
ight hours later, the viral infection medium was replaced with
ulture medium for 24 hours. The transduction procedure was
epeated 3 times. Transduction efficiency was assessed by means
f histochemical staining for lac-z expression.
Before transplantation, SkMs were also incubated in DAPI
ulture medium (20 g/100 mL) for 24 hours. Incorporation effi-
iency of DAPI was calculated by dividing the number of blue
uorescent nuclei counted by means of fluorescence microscopic t
The Journal of Thoracicnalysis by the total number of cells counted by means of phase-
ontrast microscopic analysis.
Before cell transplantation, the viability of SkMs was assessed
y using the trypan blue (0.4%, GIBCO) exclusion method.
istochemistry for lac-z Expression
he lac-z–transduced SkMs were fixed with 0.5% glutaraldehyde
or 15 minutes at room temperature. After rinsing, the cells were
ncubated overnight at 37°C with 40 mg/mL 5-bromo-4-chloro-
indoyl--D-galactosidase (Bio-Rad) prepared in 1 PBS buffer
ontaining 30 mmol/L potassium ferricyanide, 30 mmol/L potas-
ium ferrocyanide, and 2 mmol/L magnesium chloride. Next the
ells were observed with a light microscope (Olympus Co) for
reen-stained nuclei. The labeling efficiency was calculated by
ividing the number of green-colored nucleus cells counted by
eans of light microscopic analysis by the total number of cells
ounted by means of phase-contrast microscopic analysis.
yocardial Infarction Model and
xperimental Groups
rat heart model of myocardial infarction was developed in
emale Wistar rats. The animals were anesthetized with ketamine
50 mg/kg administered intraperitoneally) and xylazine (10 mg/kg
dministered intraperitoneally) and mechanically ventilated at a
idal volume of 5 mL (75 cycles/min). The infarction was created
y means of permanent ligation of the left anterior descending
oronary artery with a 6-0 polypropylene snare.
One week later, 208 animals with myocardial infarction were
ivided into 6 groups: the DMEM-injected control group 1 (n 
4); the DMEM-injected control group 2 with cyclosporine (INN:
iclosporin) treatment (n  24); the hSkM-transplanted group 3
n  40); the hSkM-transplanted group 4 with cyclosporine treat-
ent (n  40); the rSkM-transplanted group 5 (n  40); and the
SkM-transplanted group 6 with cyclosporine treatment (n  40).
he hearts were injected with a total of 150 L of DMEM without
ells or containing 3  106 hSkMs or rSkMs at 5 different sites in
nd around the infarcted area.
The animals were killed at 10 minutes and 1, 4, 7, and 28 days
fter cell transplantation. In groups 2, 4, and 6 cyclosporine (10
g · kg1 · d1 administered intraperitoneally) was adminis-
ered 5 days before cell transplantation and continuing to animal
eath. In control groups 1 and 2 there were 4 rats at each time
oint, except for 8 rats on day 28. The hearts were frozen in liquid
itrogen–cooled isopentane only for histochemical studies. (No
eart was used for polymerase chain reaction [PCR] analysis
gainst a male specific gene, sry, because in our pilot study no
ignal was detected.) In the other groups there were 8 rats at each
ime point. Four hearts were used for histochemical study, and the
hole left ventricular free wall of the remaining 4 rats was ho-
ogenized to extract DNA for PCR analysis.
uantitative Real-time PCR
he survival of male donor SkMs was evaluated by using
eal-time PCR directed at the sry gene with DNA Engine
pticon2 (Bio-Rad). The DNA from homogenized heart tissue
as extracted by using the DNeasy kit (QIAGEN), according tohe manufacturer’s instructions.
and Cardiovascular Surgery ● Volume 134, Number 5 1333
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1
TXMale genomic DNA from human subjects (Research Instru-
ents) or rats (Biochain) was used as standard after a serial
ilution (5). Real-time PCR analysis was performed with the
YBR Green kit (ABgene). Briefly, 5 L of each standard and
ample was added to the real-time PCR mixture containing the
aqMan PCR Master Mixture, primers, and fluorescent SYBR
reen. The reaction mixture was preheated for 1 minute at 95°C.
he PCR amplification protocol consisted of 45 cycles of dena-
uration for 15 seconds at 95°C and annealing and extending for 1
inute at 60°C.
The primers were as follows: human sry gene—forward 5=-
GGCGATTAAGTCAAATTCGC 3=, reverse 5=-CCCCCTAG-
ACCCGTACAATGTATT-3=; rat sry gene—forward 5=-GCCT-
AGGACATATTCTCTGGGAG-3=, reverse 5=-GCTGAT CT
TGAATTCTGCATGC-3=; rat -globin gene—forward 5=-
GCCATGAGGGTACCTTCTAGAC-3=, reverse 5=-AATTC
TTGCCCAGGTGG-3=.
istochemical and Immunohistochemical Studies
ections of 6 m were cut from frozen slices and observed under
microscope for DAPI florescence (blue). The tissue sections
ositive for DAPI were processed for further staining. Hematox-
lin and eosin staining was performed to observe the tissue archi-
ecture. To detect SkM differentiation, immunostaining was per-
ormed for skeletal myosin heavy chain fast isoform (1:50, 1 hour,
7°C; Serotec), skeletal myosin heavy chain slow isoform (1:100,
hour, 37°C; Chemicon), and biotinylated goat antipolyvalent (8
inutes, room temperature; Lab Vision) and streptavidin peroxi-
ase (8 minutes, room temperature; Lab Vision). The section was
hen developed with 3,3=-diaminobenzidine tetrahydrochloride
ubstrate for 1 minute.
The immunoreactivity was determined by immunostaining for the
nfiltration of CD4 and CD8 lymphocytes (1:50, 1 hour, 37°C; BD
harMingen) and macrophages (1:20, 1 hour, 37°C; Serotec) by using
heir specific antibodies, followed by the rhodamine-conjugated sec-
ndary antibody (1:200, 1 hour, room temperature; Chemicon). The
umbers of infiltrating macrophages and CD4 and CD8 lym-
hocytes were counted by using light microscopy. In the process of
ounting the cell numbers, 5 sections positive for DAPI were
hosen in each rat, 3 sections in the middle of the infarction, and
sections at remote regions. For each section, 3 fields were chosen
t 400 magnification.
eart Function Assessment
eart function was assessed by means of 2-dimensional echocar-
iography at 6 days after infarction as baseline determinations and
weeks after SkM transplantation to show the efficacy of SkM
ransplantation. Two-dimensional (and M-mode) measurements
ere performed with a 10-MHz linear array transducer system
GE). Parasternal long-axis views were obtained to view the re-
ional wall-motion abnormalities. Short-axis M-mode views were
btained perpendicular to the midventricular level, with sweep
peeds of 200 mm/s confirmed by means of 2-dimensional echo-
ardiography. To obtain a measure of systolic function, dimen-
ional fractional shortening (FS) and ejection fraction (EF) were
omputed by using the following formulas: FS  LVED 
VES ⁄ LVED 100% and EF  LVED2  LVES2 ⁄ LVED2
00%, where LVED is defined as left ventricular end-diastolic F
334 The Journal of Thoracic and Cardiovascular Surgery ● Novimension and LVES is defined as left ventricular end-systolic
imension.
tatistical Analysis
he data were analyzed with SPSS 12.0 software (SPSS, Inc). All
alues were expressed as the mean  standard error of the mean.
ne-way analysis of variance with the post-hoc Tukey test was
erformed to assess the significant difference among multiple
roups. The significant difference between 2 groups was evaluated
y using the Student t test.
esults
he development of myocardial infarction resulted in an
1.9% (28/236) acute mortality rate within 24 hours. All
08 surviving animals survived the cell transplantation pro-
edure and continued for the full length of the experiment.
haracterization of SkMs
he purity of hSkMs and rSkMs was 98.89% and 75.35%,
espectively, for desmin expression when gated for control
t 1.02% by means of flow cytometric analysis (Figure
1, A2, B1, and B2). The efficiency of DAPI and lac-z
abeling was 100% and 85%, respectively (Figure E1, C
2, and D). Trypan blue dye exclusion showed greater than
5% viability of the cell preparations before transplantation.
ell Survival After Transplantation in Infarcted
at Hearts
xtensive survival and differentiation of SkMs was ob-
erved in the infarcted rat hearts after engraftment. Until
ay 7, the transplanted cells were found clustered at the site
f injection without any orientation (Figure E2, A). By day
8, the transplanted SkMs were seen to be aligned and well
riented, which might result from the differentiation of
kMs (Figure E2, B).
On days 1 and 4, we did not detect any skeletal myotube
ormation. This was shown by the lack of skeletal myosin
ast chain and slow chain immunostaining. On day 7, ap-
roximately one third of the samples were positive for
keletal myosin fast chain, but none of them were positive
or skeletal myosin slow chain. On day 28, almost all
amples were positive for skeletal myosin fast chain, and
pproximately half of the samples were positive for slow
hain by means of immunostaining (Figure E2, D–F). The
mplanted cells expressed myosin slow chain, which was
ore adaptable for cardiac pump function. The extensive
urvival of the engrafted cells was also confirmed by means
f lac-z staining (Figure E2, G) and real-time PCR for t
ry gene from the male transplanted SkMs in female hearts.
mmune Cell Dynamics After SkM Transplantation
mmunostaining for macrophages and CD4 and CD8
ells and their counts at different time points are shown in
igure 1.
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TXMacrophages were the first cells infiltrating into the
onor myoblast pockets (Figure 1, A and B). Immediately
fter cell transplantation (10 minutes), macrophages were
Figure 1. Immunostaining and observation of time of in
and CD4 cells (E and F) into the cell injection site
infiltrating cells (including macrophages, CD4 cells
(groups 3 and 5 vs group 1; groups 4 and 6 vs group 2, P
(including macrophages, CD4 cells, and CD8 cells)
not receiving cyclosporine treatment (group 4 vs grouarely observed at the site of the cell graft. After 24 hours, n
The Journal of Thoracicn intense infiltration by macrophages was apparent in all
he transplanted hearts. In group 3 the average number of
acrophages was 45.8  4.55 (control, 6.8  0.86). The
tion of macrophages (A and B), CD8 cells (C and D),
nification 400). *Significantly increased numbers of
CD8 cells) compared with those of groups 1 or 2
1). #After cyclosporine treatment, the infiltrating cells
ficantly decreased compared with those in the groups
nd group 6 vs group 5, P < .01).filtra
(mag
, and
< .0
signiumber of macrophages showed a gradual increase and
and Cardiovascular Surgery ● Volume 134, Number 5 1335
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1
TXeached 51.6 3.98 (control, 6.8 0.87) on day 4 and then
eaked on day 7 (54.2 4.3; control, 7.8 1.66). After day
, the number of macrophages started to decrease and
argely decreased to a low level on day 28 (17  1.95;
ontrol 1, 8.8 1.16). In groups 4, 5, and 6 the macrophage
umbers on days 1, 4, 7, and 28 were significantly decreased
ompared with those in group 3 (P  .05). On day 28, the
acrophage numbers in groups 5 and 6 were as low as those
n the control groups (P  .10).
CD8 cell infiltration is shown in Figure 1, C and D. In
roup 3 the number of CD8 cells infiltrating was 7  0.63
control, 3.4  0.51) on day 1, 22  2.10 (control, 2.8 
.66) on day 4, and 40.8  2.87 (control, 3.4  0.51) on
ay 7. There were no significant differences between the
umber of CD8 cells in group 3 (4.8  0.58) and in
ontrol group 1 (3.4  0.75) on day 28. In groups 4, 5, and
the CD8 cell numbers on days 4 and 7 were largely
ecreased compared with those in group 3. On the other
and, CD4 cells infiltrated from day 4 (Figure 1, E and F).
n group 3 the numbers were 20.4  2.14 (control, 3 
.84) and 30.4  0.72 (control, 3  0.71) on days 4 and 7,
espectively. In groups 4, 5, and 6 CD4 cell numbers on
ays 4 and 7 were largely decreased compared with those
een in group 3 (P  .05). CD4 cell numbers on day 28 in
he cell-transplanted groups were as low as those in the
ontrol group.
ime Course of Xeno- and Allo-SkM Survival
able 1 shows the quantification of SkMs at different 
oints after cell engraftment. There was no significant dif-
erence in the actual quantity of sry copies at 10 minutes
mong groups (1-1.2  106 SkMs were left), and the
verage SkM number at 10 minutes after cell transplantation
as used as baseline. In the SkM transplantation groups
groups 3–6) a remarkably rapid and massive loss of male
NA was observed after injection of male SkMs. A total of
4.6%, 90.7%, 91.2%, and 88.9% of the SkMs were lost in
roups 3, 4, 5, and 6, respectively, during the first 24 hours.
hese observations are consistent with earlier findings re-
able 1. The time courses of SkM survival
Group 3
(xeno-SkM graft)
Group 4
(xeno-SkM  cyclosp
0 min 100% 100%
ay 1 5.37% 0.8% 9.26%  0.9%
ay 4 9.01% 1.2% 15.55%  1.6%
ay 7 17.23% 2.8% 31.36%  2.7%
ay 28 23.63% 1.8% 54.68%  3.9%
he corresponding numbers (means standard error of the mean) are copy
y the copy numbers of male DNA at 10 minutes. *Significant difference co
and group 5 vs group 6, P  .01). †Significant difference compared with
, P  .05).orted by other groups.1,12 Subsequently, the number of g
336 The Journal of Thoracic and Cardiovascular Surgery ● NovkMs showed a gradual increase until 4 weeks, which was
robably a result of proliferation of surviving SkMs.
We also have shown the role of host immune response in
onor SkM survival. In xeno-SkM–transplanted group 3, 5.37%
nd 23.63% of SkMs were left on days 1 and 28, respectively.
oth cyclosporine-treated xeno-SkM–transplanted group 4
nd allo-SkM–transplanted group 5 showed a significant
ncrease in total number of SkMs (P  .01, Table 1)
urthermore, in group 6 allogeneic SkMs with cyclosporine
reatment showed a superior survival in the host myocar-
ium compared with the other cell-grafted groups (P .05).
eart Function Assessment
igure 2 shows heart function improvement by mean
chocardiography with SkM transplantation. There was no
ignificant difference in baseline heart performance (EF and
S) among the different groups. The EF and FS baselines in
roups 1 through 6 were 43.50% 2.6% and 24.80% 1.7%,
3.75%  3.8% and 23.50%  1.2%, 43.00%  1.8% and
4.50% 1.3%, 43.30% 2.9% and 25% 1.6%, 43.4%
.73% and 25.3%  1%, and 44.3%  3.0% and 25.5% 
.65%, respectively. Four weeks after SkM transplantation,
he EF and FS values in groups 1 through 6 were 44% 
.4% and 25.5%  1%, 44.13%  3.4% and 26.25% 
.75%, 49%  1.5% and 28.8%  2.2%, 52.5%  1.2%
nd 31% 0.8%, 50.33% 2.07% and 31% 2.12%, and
4.2%  1.57% and 31.25%  2.22%, respectively. Sig-
ificant improvement of EF and FS were observed com-
ared with baseline values (within-group comparison) in
roups 3 through 6 (P  .01), whereas no functional im-
rovement in the DMEM-treated groups was observed
groups 1 and 2). When compared with those of groups 1
nd 2, there was significant improvement of EF and FS
alues in all SkM transplantation groups (groups 3 and 5 [no
yclosporine treatment] vs group 1 and groups 4 and 6
cyclosporine treatment] vs group 2, P  .01). In groups 4
nd 6, receiving both SkMs and cyclosporine, EF improved
ignificantly compared with that seen in the groups not
eceiving cyclosporine treatment (group 4 vs group 3 and
)
Group 5
(allo-SkM graft)
Group 6
(allo-SkM  cyclosporine)
100% 100%
8.83% 1.5%† 11.10% 1.3%*†
12.99% 2.1%† 26.80% 4.3%*†
20.69% 3.4%† 49.73% 5.9%*†
33.55% 5.5%† 67.87% 5.6%*†
bers of male DNA from the hearts harvested at different time points divided
ed with the groups not receiving cyclosporine treatment (group 3 vs group
geneic transplantation groups (group 3 vs group 5 and group 4 vs grouporine
*
*
*
*
num
mpar
xenoroup 6 vs group 5, P  .05). However, even though SkMs
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TXurvived better in the allogeneic transplantation groups
34% of SkMs in group 5 and 68% of SkMs in group 6)
ompared with the xenogeneic groups (24% in group 3 and
5% in group 4), EF did not show any significant difference
group 5 vs group 3 and group 6 vs group 4, P  .1). This
ight be a result of the fact that the extent of cell survival
ncrease (from 24% to 34% and from 55% to 68%) was not
s large as that in groups treated with cyclosporine (from
4% to 55% and from 34% to 68%). Actually, a previous
tudy has demonstrated a dose–response effect of SkMs on
mprovement of heart function.13 However, if the increas
f cell survival is not big enough, it might not result in
ignificant improvement in heart function.
iscussion
llomyoblasts and xenomyoblasts provide alternative sources
or myoblast-based cardiac cell therapy. However, the issue of
ost immune responses hampers their clinical application. This
tudy was mainly carried out to investigate host immune cell
inetics, survival profile of the donor SkMs, and SkM graft
fficacy after xenogeneic and allogeneic transplantation into
nfarcted myocardium. We observed the SkM survival dy-
amics in an infarcted heart and demonstrated that the
mmunocytes, including CD4 cells, CD8 cells, and mac-
ophages, severely infiltrated during the acute stage after
yoblast transplantation and then subsided. Furthermore,
yclosporine treatment inhibited the early infiltration of
mmunocytes, promoted myoblast survival, and improved
Figure 2. Echocardiographic analysis showed improv
There was no significant difference in baseline heart p
[FS]) among the different groups of animals. Within gr
after skeletal myoblast transplantation (groups 3–6) co
no functional improvement in the DMEM-treated group
improvement of EF/FS compared with that seen in c
cyclosporine treatment). †Significant improvement of
cyclosporine-treated groups, P < .01). In the EF arm (A)
level compared with that seen in the groups not recei
6 vs group 5, P < .05). No significant improvement w
xenogeneic groups (group 5 vs group 3 and group 6 vs
observed in the skeletal myoblast transplantation groueart function. These findings suggest the feasibility of SkM s
The Journal of Thoracicransplantation from nonautologous sources, especially
llomyoblasts.
Most previous studies have used hSkMs for autologous
ransplantation,7,8 which has left the in vivo behavior
SkMs poorly studied. In 2003, Pagani and colleag9
ere the first to show direct evidence for hSkM survival and
ifferentiation into mature myofibers in myocardium. Later,
agege and associates10 also demonstrated the viability an
ifferentiation of hSkM grafts. However, to further inves-
igate the fundamental cellular behavior of hSkMs, in par-
icular their surviving efficiency after transplantation into a
ardiac environment, a small-animal model in which whole
raft cells could be easily collected and quantified after
nimal death would be ideal. In our study a rat heart
nfarction model was used.
Our study has shown the early dynamics of SkMs, which
nables us to have a better understanding of the early
ellular behavior of SkMs in vivo, especially hSkMs. In our
tudy, at 10 minutes after SkM transplantation, only 1 to
.2  106 SkMs were left, and then majority of the remain-
ng SkM signals were rapidly lost by day 1 after cell
ransplantation. Previous studies have described this rapid
yoblast loss after implantation into skeletal muscles and
ormal heart tissue1,12,14,15 and have attributed this massi
ell loss to mechanical loss, including mechanical leakage
nd washout,16,17 cell redistribution to other organs,18 and
ell death.1,12,14,15 The present study used a myocard
nfarction model, which is more similar to the clinical
eart function after skeletal myoblast transplantation.
ance (ejection fraction [EF] and fractional shortening
, significant improvement in EF and FS was observed
ed with baseline values (P < .01), whereas there was
roups 1 and 2). Between-group analyses: *Significant
l group 1 (comparison among groups not receiving
compared with control group 2 (comparison among
h cyclosporine treatment, EF increased to a significant
cyclosporine treatment (group 4 vs group 3 and group
bserved in allogeneic groups compared with that of
up 4). In the FS arm (B) no significant difference was
roups 3-6) after cell therapy.ed h
erform
oups
mpar
s (g
ontro
EF/FS
, wit
ving
as o
gro
ps (gettings. Furthermore, there was no significant difference in
and Cardiovascular Surgery ● Volume 134, Number 5 1337
aw
c
s
g
t
m
t
t
p
fi
l
p
b
t ed
g
f eg
u
t
fi
s
a
w
h
a g
t
o
d
r
m
w
l
S
c
i
m
s
o
t f
t
w
l er
a
m to
m
d
c
t
a
s
m
m
t as
b
S
t
w
I
l
b
t
c
b
a
c
g
i
x
m
t
t
v
i
i
s
r
d
(
p
9 te
t
t
s
p
t
d
e
s
i
g
f
n
d
n
w
a
s
R
Cardiothoracic Transplantation Guo et al
1
TXctual quantity of sry copies at 10 minutes among groups,
hich might exclude the effects of immunoresponses on
ell loss in the first 10 minutes. After 10 minutes, cell
urvival rates changed among various SkM transplantation
roups, which suggested an immune rejection effect during
his phase. After day 1, a gradual increase in the number of
yoblasts was observed until 4 weeks after cell transplan-
ation, resulting from the SkM proliferation outbalancing
he gradual loss. Previous studies have shown that SkM
roliferation is stimulated by several growth factors, such as
broblast growth factor 2, epidermal growth factor, insulin-
ike growth factor 1, and stem cell factor.19 Because SkM
roliferation stops on differentiation, the proliferation might
e enhanced by TGF-, which represses myoblast differen-
iation.20 In addition, some isoforms of platelet-deriv
rowth factor also regulate myoblast proliferation and dif-
erentiation.21 To our knowledge, the mechanism that r-
lates SkM proliferation remains unclear after transplanta-
ion into the myocardium, which might be an interesting
eld for future investigation. Of greater significance, our
tudy showed that the grafted hSkMs and rSkMs survived
nd differentiated well in the immunocompetent hosts, even
ithout any immunosuppression. Previous animal studies
ave accumulated some evidence of xenomyoblast22 and
llomyoblast23,24 transplantation into myocardium. Usin
he minimal dosage of cyclosporine (5 mg · kg1 · d1)22
r without immunosuppressive treatment,23,24 they have
emonstrated SkM acceptance. More recently, our group
eported a 7-month survival of xenomyoblasts by using a
inimal dose of cyclosporine (5 mg · kg1 · d1) for 6
eeks after transplantation into the infarcted hearts.5 In
ight of these data and our present study, we suggest that
kMs enjoy a nonautologous graft acceptance in the myo-
ardium, a finding that might have far-reaching implications
n clinical perspective. The nonautologous graft acceptance
ight result from the relatively privileged transplantation
ite of the myocardium, where presentation and recognition
f human leukocyte antigen might not take place because of
he lack of a lymphatic drainage system,25 and the nature o
he cells with less expression of human leukocyte antigen,
hich might be due to the differentiation of SkMs, estab-
ishment of chimerism, or both.2,6 On the other hand, oth
uthors showed that allogeneic myoblasts were highly im-
unogenic.14,26 However, they transplanted myoblasts in
uscle tissue, not heart tissue, which might explain the
iscrepancy.
Another important finding of our study is the negative
orrelation between the number of immunocytes and the
otal number of SkMs. Allomyoblasts and xenomyoblasts
re typically rejected by the host immune system in re-
ponse to inherent histoincompatibility. Even autologous
yoblasts can induce immune responses toward antigenic
olecules expressed after exposure to tissue culture condi-
338 The Journal of Thoracic and Cardiovascular Surgery ● Novions or transfer of genes.27 The host immune response h
een a confounding factor in the better understanding of
kM survival after transplantation. Surprisingly, we found
hat immunocytes infiltrated severely only within the first
eek after myoblast transplantation into the infarcted heart.
mportantly, the number of infiltrating immunocytes was
argely decreased to a low level after 4 weeks, which might
e attributed to the allomyoblast or xenomyoblast differen-
iation. Our study demonstrated a significant role of immune
ells in the early death of donor SkMs, which is supported
y close correlation between the number of immunocytes
nd the total number of SkMs shown in our study. In
yclosporine-treated groups or in allogeneic transplantation
roups, SkMs survived better in the more immunocompat-
ble condition (less immunocytes infiltrated) compared with
enogeneic transplantation.
From our study, administration of cyclosporine (10
g · kg1 · d1 starting 5 days before cell transplan-
ation and continuing to animal death) restrained the infil-
ration of the immunocytes, therefore enhancing SkM sur-
ival and improving heart performance. This has significant
mplications, especially in clinical cases. The dosage and
nitiation time of cyclosporine administration in the present
tudy were very similar to those reported in the first case
eport of allomyoblast transplantation for coronary artery
isease, which showed that administration of cyclosporine
5-7 mg · kg1 · d1 beginning 5 days before cell trans-
lantation and lasting for 8 weeks) was effective and led to
-month retention of hSkMs.28 It is recommended to initia
he cyclosporine treatment several days before cell therapy
o achieve a stable blood concentration of cyclosporine and
ufficient immunosuppression before cell transplantation
rocedures, because the immunocytes infiltrate severely in
he acute phase after SkM transplantation. In our study, on
ay 28, the immunocytes subsided compared with levels at
arlier time points. This suggests early cessation of cyclo-
porine treatment (off cyclosporine at 8 weeks after graft-
ng, as performed in the clinical case report) in nonautolo-
ous SkM transplantation. However, the effects need to be
urther monitored both in animal studies and clinical cases.
In conclusion, allomyoblasts survive better than do xe-
omyoblasts after transplantation into infarcted myocar-
ium. After inhibition of immunocyte infiltration by immu-
osuppressive treatment, the SkM survival is enhanced,
ith improved heart performance. This suggests that non-
utologous SkM transplantation is feasible with immuno-
uppressive treatment, especially for allomyoblasts.
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1
TXFigure E1. Immunostaining
and flow cytometric assay of
skeletal myoblasts for desmin
and 4=,6=-diamidino-2-phenylin-
dole hydrochloride and lac-z la-
beling efficiency. A1, Green flu-
orescent cytoplasm showing
desmin-positive skeletal myo-
blasts. A2, Human skeletal myo-
blasts were 98.89% pure (blue
curve) for desmin expression
when gated for control at 1.02%
(red curve) by means of flow
cytometric assay. B1, Desmin-
positive rat skeletal myoblasts.
B2, Rat skeletal myoblastswere
75.35% pure (blue) for desmin
expressionwhen gated for con-
trol at 1.02% (red) by means
of flow cytometric assay. C1,
4=,6=-Diamidino-2-phenylindole
hydrochloride–labeled skeletal
myoblasts (blue nuclei). C2,
Merged image of panel C1 and
phase-contrast image to show
total number of cells. D, Lac-z–
positive cells with green nuclei.
(Original magnification: 200).339.e1 The Journal of Thoracic and Cardiovascular Surgery ● November 2007
Guo et al Cardiothoracic TransplantationFigure E2. Myoblast survival
and differentiation after trans-
plantation. A, 4=,6=-Diamidino-
2-phenylindole hydrochloride–
labeled skeletal myoblasts 7
days after transplantation.
Note the presence of cells
at the injection site without
orientation. B, 4=,6=-Diamidino-
2-phenylindole hydrochloride–
labeled skeletal myoblasts
28 days after transplantation
showed typically aligned ori-
entation, which followed host
muscle architecture. C, Hema-
toxylin and eosin staining to
show the myocardium of con-
tinuous section from panel B.
D, Myosin heavy chain (slow
isoform) immunostaining coun-
terstained with hematoxylin to
show myoblast differentiation
and (E). F, Myosin heavy chain
(fast isoform) immunostaining
counterstained with hematox-
ylin. G, Myoblast survival con-
firmed by lac-z staining (green
nuclei) counterstained with
hematoxylin. (Original magnifi-
cations: A-D, 100; E-F, 800;
G, 400).The Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 5 1339.e2
TX
